Skip to content

Catalyst Pharmaceutical CPRX Net gains (losses) on investments

Net gains (losses) on investments at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.21M+56.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$18.28M-17.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$25.3M+183%
TG Therapeutics logo
TG TherapeuticsTGTX
$1.53M+1,575%
Biogen logo
BiogenBIIB
$19M+146%
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's net gains (losses) on investments?
Catalyst Pharmaceutical (CPRX) reported net gains (losses) on investments of $4.75M in Q1 2026.
How has Catalyst Pharmaceutical's net gains (losses) on investments changed year-over-year?
Catalyst Pharmaceutical's net gains (losses) on investments increased by 79.7% year-over-year, from $2.64M to $4.75M.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.